RFK Jr. Visits the CDC Following Deadly Attack on the Agency
Save
Health and Human Services Secretary Robert F. Kennedy Jr. is visiting the US Centers for Disease Control and Prevention on Monday following the deadly attack on the Atlanta-based agency on Aug. 8, according to people familiar with the plans.
It wasn't immediately clear who he would be meeting. CDC Director Susan Monarez confirmed Friday night the attack was on the CDC building in a post to her X account. CDC believes Patrick Joseph White, a resident of a northern Atlanta suburb, targeted the agency because of his views related to the Covid vaccine, the agency's chief operating officer Christa Capozzola said in an email viewed by Bloomberg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
2 minutes ago
- News24
The #presentdads movement inspires a new generation of involved fathers
Let's be real, fatherhood isn't what it used to be. Gone are the days when dads were just the breadwinners, the stern 'wait until your father gets home' voice, or the guy on the sidelines of family life. Today, a new wave of men is stepping up to be equal partners in parenting, and it's about time. The #presentdads movement celebrates hands-on fatherhood. It's about showing up—not just for big milestones like birth but every messy, chaotic, beautiful moment in between. This shift isn't just trendy (though it's Instagram-worthy!); it's crucial. Because here's the truth: there's still a lot of room for improvement. Did you know over 67% of Black children grow up in single-mother households? For contrast, it's about 24% of White children in the same situation. That's not just statistics—it's the reality for millions of families, and it shows how important it is to rethink fatherhood. Imagine the ripple effects if more dads embraced being present, fully engaged, and connected. So, what does it really mean to be part of this dad evolution? We're not just talking about attending a few soccer games or doing the occasional diaper change. Nope—it's deeper than that. Anathi Gusha, Dis-Chem Clinic Regional Manager, explains it best: 'Fathers are rewriting the fatherhood manual. They're more hands-on, emotionally available, and intentional about being there for mum and baby long before the baby arrives. Their presence—and let's be real, their effort—makes all the difference.' Read more| SPECIAL REPORT | Why do so many women and children go missing? Here are some practical tips on how to get involved: 1. Be Mum's Health MVP Pregnancy is no joke. From wild cravings to swollen feet, mum is going through a LOT—so your job is to have her back. Go to antenatal checkups, help her stick with healthy routines, and pay attention to her needs (yes, sometimes all she really wants is her favorite snack on demand). Advocating for her health isn't extra—it's credit? Learn about the scary stats some women face with maternal healthcare. Showing up as her advocate could make all the difference. 2. Emotional Support Matters (Big Time) Let's have a moment of truth: pregnancy and parenting can feel overwhelming—an emotional rollercoaster of good days, rough nights, and WTF-is-happening moments. For mums, that emotional strain is real. Even when she doesn't say it, she needs you to listen, be present, and reassure her that you're in this is key. Never underestimate the power of just being there—even if that means holding her hand in silence after a tough day. 3. Own the Birth Plan Like a Boss When the big day comes, she's going to need you—not on the sidelines, but in the room (figuratively and literally). Work on the birth plan together: from her pain relief preferences to what she'll need when things get intense during delivery? Stay calm. You're not just her partner; you're her rock. 4. Logistics: The Secret Weapon Want to make a huge impact without even needing superhero powers? Master the logistics. Packing the hospital bag, setting up the nursery, stocking the snack shelf—these small acts make a BIG difference. She'll notice. Trust me. Pro tip: Keep those phone chargers (and snacks) close! Hungry and uncharged is not the vibe for new parents. 5. Learn the Basics (You've Got This) No one is born knowing how to swaddle, prep bottles, or calm a screaming newborn at 2 a.m.—but that's where parenting classes or YouTube come in clutch. Embrace your inner student and learn the essentials. Not only does this make you more confident, but it also shows her you're in this 50/50. Let's not sugarcoat it: the stakes are high. A hands-on dad can transform the household dynamic for the better. Whether it's helping reduce maternal stress, fostering healthy development for the baby, or just being a consistent, loving presence, your involvement fathers in Black communities, showing u p takes on an even deeper meaning. By breaking cycles of absenteeism and setting a new standard of fatherhood, you're not just reshaping the family—you're rewriting the legacy for future generations.
Yahoo
29 minutes ago
- Yahoo
Integrum secures top sponsorship title at the Global Collaborative Congress on Osseointegration exclusively for the next three years
MÖLNDAL, Sweden, Aug. 13, 2025 /PRNewswire/ -- Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), the provider of the OPRA™ Implant System, has announced that it has secured the exclusive title of Legacy Sponsor - the highest level of sponsorship - for the Global Collaborative Congress on Osseointegration (GCCO) annual meeting, held in Charlotte, North Carolina, USA. This multi-year sponsorship grants Integrum exclusive top-tier recognition for the next three years and underscores the company's long-standing commitment to clinical education, surgical innovation, and international collaboration in the field of osseointegration, known as bone-anchored prosthetics. As a Legacy Sponsor, Integrum will continue to support the global limb loss community by fostering research, advancing outcomes, and engaging cross-disciplinary education. "We're proud to serve as top sponsor of the GCCO conference. This partnership reflects our shared commitment to facilitating innovation and fostering global collaboration to expand limb loss care. We believe in the power of shared knowledge and scientific evidence to drive long-term impact," said Jeffrey Zanni, President of Integrum Inc. The GCCO conference brings together leaders in surgical innovation, rehabilitation, prosthetics and clinical research to further the progress being made in the field of bone-anchored prosthetics. "Integrum's support has been instrumental in driving forward the mission of GCCO-to unite experts across borders to advance limb loss care. Their commitment to innovation and education elevates the quality of our conversations and enables us to continue improving outcomes for amputees worldwide," said Dr. Joseph Hsu, conference chair and orthopedic trauma surgeon. Integrum's top sponsorship reflects its mission to provide freedom of mobility for every person by driving improved outcomes and greater access to advanced prosthetic solutions. The company remains committed to supporting GCCO's mission and upholding shared objectives within the osseointegration space. For more information about Integrum or the OPRA™ Implant System, visit For registration and more information about the GCCO conference visit For more information, please contact:Jeffrey Zanni, President USEmail: +1 617-839-1600 Jörgen Svanström, CFOMobil: +46 (0) 7073 496 60,Email: Certified Adviser The Company's Certified Adviser is DNB Carnegie Investment Bank AB. This information was brought to you by Cision The following files are available for download: Press Release GCCO 2025 2025-08-13 eng View original content: SOURCE Integrum AB 登入存取你的投資組合
Yahoo
29 minutes ago
- Yahoo
2 Stocks Down More Than 90% That Still Aren't Worth Buying
Key Points Teladoc Health and Tilray Brands have lost significant value over the past five years. Teladoc is posting slow growth and consistent net losses, with little hope of a turnaround. Tilray faces several roadblocks in the highly regulated cannabis industry. 10 stocks we like better than Teladoc Health › While basic investing wisdom advises us to "buy low," no point is low enough when there's hardly any hope that a stock will bounce back. In other words, no matter how much a company lags the market, sometimes it still isn't attractive. In my view, that's the case with Teladoc Health (NYSE: TDOC) and Tilray Brands (NASDAQ: TLRY), both of which have lost more than 90% of their market value over the past five years. Their stocks still aren't worth buying, though. Here's what investors need to know about these companies. 1. Teladoc Health Teladoc, a telemedicine specialist, experienced a surge in popularity in 2020, as people were confined to their homes and had limited options for accessing medical care. Patients can access basic consultations, prescriptions, and referrals through telemedicine platforms. Teladoc helped provide that, but the company's fortunes turned in 2021. Demand for its services declined as government-imposed lockdown measures expired. The company also experienced consistent, and sometimes significant, net losses. Furthermore, BetterHelp, Teladoc's virtual therapy service and one of its main growth drivers during this period, also started facing challenges. BetterHelp encountered stiff competition, which ate into its market share. Due to all these issues, Teladoc's revenue has been growing very slowly -- if at all -- for the past few quarters, and the company remains unprofitable. Teladoc is looking to turn things around. One bright spot in the company's recent financial results has been its international expansion efforts. International revenue has been growing at a faster rate than in the rest of its business. If it can continue setting roots in countries outside the U.S., it could exploit meaningful growth opportunities there, or so the argument goes. Since the company's ecosystem remains deep -- with approximately 102 million integrated-care members -- Teladoc also hopes that it can grow revenue by cross-selling additional products to its existing members. While these plans sound good in theory, it's doubtful that Teladoc can pull them off. The telehealth specialist's efforts abroad might increase its already high expenses and make it harder for the company to turn profitable. And while cross-selling more products to existing members might be a great idea, Teladoc has failed to make meaningful progress in the past few years through this route. Maybe the company will eventually turn that around, but there's little reason to believe it will. The stock looks likely to remain southbound for some time, which is why it's best to avoid it. 2. Tilray Brands Tilray is a leader in the cannabis industry. The company offers a suite of products across both recreational and medical channels in Canada, the U.S., Germany, and several other countries. In Canada, Tilray still has the leading market share. However, none of that has allowed the company to perform well in recent years. It's not entirely Tilray's fault, since the cannabis industry faces significant regulatory challenges in the U.S.; the substance remains illegal at the federal level. Even in Canada, where medical and recreational uses of cannabis are legal, there have been challenges for the business, including oversupply. Although Tilray has the leading market share in Canada, the landscape has been challenging enough that it hasn't been able to grow its top and bottom lines consistently. In fairness, Tilray is now a fairly diversified company. It has expanded its craft brewing business, and also purchases and resells various pharmaceutical products in Germany through its distribution segment. The final business unit, "wellness," involves the production and sale of hemp-based foods. That said, diversification has had little impact on improving Tilray's financial results. So the company continues to rely on potential regulatory progress in the cannabis market. CEO Irwin Simon thinks recreational uses of cannabis will be legal in the U.S. by the end of President Donald Trump's second term. That's one reason the company expanded its craft brewing business in the U.S. through acquisition -- so it can sell drinks infused with THC and CBD when that happens. Tilray hopes that once legalization lands, it will be able to hit the ground running and dominate the markets for both recreational cannabis and cannabis-infused drinks, thanks to its existing footprint. However, there's no guarantee that this scenario will materialize anytime soon. While Tilray's shares recently soared on news that Trump could reclassify marijuana from a Schedule I substance to Schedule III, that's some ways away from federal legalization. It would be progress, to be clear. Schedule I drugs are considered to have the highest potential for abuse; that's not the case for Schedule III substances. However, marijuana would remain a controlled substance, still subject to heavy regulations at the federal level. But even under Simon's best-case scenario -- not just rescheduling but full-blown legalization -- we learned from our neighbors to the north that it's no guarantee of success for cannabis players. Tilray could encounter many of the same issues it faced in Canada. These included an initially complicated retail licensing system, stiff competition, and oversupply. In short, there's little hope that Tilray can bounce back anytime soon. The stock isn't worth investing in today. Should you buy stock in Teladoc Health right now? Before you buy stock in Teladoc Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Teladoc Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. 2 Stocks Down More Than 90% That Still Aren't Worth Buying was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
